Table 1. Primers targeting human integrins, E-cadherin and vimentin.
Target | Forward primer (5'-3') | Reverse primer (5'-3') |
---|---|---|
Alpha1 | GGTTCCTACTTTGGCAGTATT | AACCTTGTCTGATTGAGAGCA |
Alpha2 | GGAACGGGACTTTCGCAT | GGTACTTCGGCTTTCTCATCA |
Alpha3 | AAGGGACCTTCAGGTGCA | TGTAGCCGGTGATTTACCAT |
Alpha6 | TTGAATATACTGCTAACCCCG | TCGAAACTGAACTCTTGAGGATAG |
Alpha7 | CTGTTTCAGCTACATTGCAGTC | GCCTGGTGCTTGGGTTCT |
AlphaV | AATCTTCCAATTGAGGATATCAC | AAAACAGCCAGTAGCAACAAT |
Beta1 | GAAGGGTTGCCCTCCAGA | GCTTGAGCTTCTCTGCTGTT |
Beta4 | AGACGAGATGTTCAGGGACC | GGTCTCCTCTGTGATTTGGAA |
Beta5 | GGAGCCAGAGTGTGGAAACA | GAAACTTTGCAAACTCCCTC |
Beta6 | TCAGCGTGACTGTGAATATCC | GTGACATTTGGAGCTGTTCAC |
Beta8 | AATTTGGTAGTGGAAGCCTATC | GTCACGTTTCTGCATCCTTC |
Actin | GCTGTGCTACGTCGCCCTG | GGAGGAGCTGGAAGCAGCC |
CycloA | CTCGAATAAGTTTGACTTGTGTTT | CTAGGCATGGGAGGGAACA |
E-Cadherin | ACAGCCCCGCCTTATGATT | TCGGAACCGCTTCCTTCA |
Vimentin | AAGAGAACTTTGCCGTTGAA | GTGATGCTGAGAAGTTTCGT |